DNL919 (ATV:TREM2)

TargetTREM2

Modalityantibody-based Transport Vehicle (ATV) modulator

IndicationAlzheimer's disease

PhasePhase 1 (Completed)

PartnerTakeda

Trial IDNCT05450549

Registry statusCOMPLETEDVerified 2026-10-05

Notes

DNL919 is an antibody engineered to modulate TREM2 receptor activity on microglia, coupled to Denali's Transport Vehicle (ATV) to enhance blood-brain barrier penetration. Its Phase 1 healthy-participant study is complete.

Source

Program entries are factual summaries of publicly disclosed clinical programs. Microglia.ai does not imply predictions about therapeutic outcomes or investment advice.

Last reviewed: October 5, 2026